asxan.ai Agents Hub

Beta-Glucan

Evidence Fact Sheet

A family of polysaccharides with two main structural types — cereal β-1,3/1,4-glucan (oats / barley) and yeast / mushroom β-1,3/1,6-glucan — that have distinctly different mechanisms, evidence bases, and regulatory pathways. The structural distinction is the most important fact on this page.

Last reviewed · How we assess evidence →

Quick Summary

Beta-Glucan (β-glucan) is not a single molecule but a family of polysaccharides with two main structural and functional types — and the distinction matters more for this ingredient than for almost any other entry on this hub. Cereal β-1,3/1,4-glucan from oats and barley is a viscous soluble fiber that, at intakes of ≥3 g/day, has been shown across multiple meta-analyses (Whitehead 2014 · Ho 2016 · Yu 2022) to lower blood LDL cholesterol — and at ≥4 g per 30 g of available carbohydrates per meal, to reduce post-meal blood glucose rise. Cereal β-glucan holds two formal regulatory authorizations uncommon in the supplement category: the US FDA 21 CFR 101.81 health claim (since 1997) that soluble fiber from oats or barley may reduce the risk of coronary heart disease; and the EU EFSA Regulation 432/2012 Article 13(1) function claims for cholesterol maintenance and post-meal glucose response, plus the Article 14 disease risk reduction claim for cholesterol lowering and heart disease risk. In Brazil, β-glucan is recognized by ANVISA IN 28/2018 Anexo I as an authorized supplement constituent (Beta-glucana de farelo de aveia + Beta-glucana de levedura) under RDC 243/2018 framework, but without a specific Anexo V alegação funcional for β-glucan (Anexo V fiber claims are limited to psyllium ≥ 7 g/day and chitosan ≥ 3 g/day) — Brazilian labeling cannot use a verbatim ANVISA-authorized functional claim equivalent to FDA / EFSA, and cross-border product compliance requires market-specific claim wording. Yeast and mushroom β-1,3/1,6-glucan are structurally and mechanistically different — they act as innate-immune receptor ligands (Dectin-1 / CR3) rather than as a viscous cholesterol-lowering fiber — and randomized evidence (Auinger 2013 · Fuller 2017 · Zhong 2021 meta-analysis) supports a modest role in immune system function in adult populations, with effect sizes comparable to vitamin D in respiratory immune research. Yeast and mushroom β-glucan have no EFSA-authorized health claim in the EU and are sold there as dietary supplements without immune claims. Mushroom-derived AHCC (Active Hexose Correlated Compound, from shiitake mycelium) has emerging pilot data in immune research contexts; current evidence does not support disease-treatment claims. Individuals with autoimmune disease, recent organ transplant or active immunosuppressive therapy, or glycogen storage disease should consult a healthcare provider before starting yeast or mushroom β-glucan supplementation.

Overview · What is Beta-Glucan?

Beta-Glucan (β-D-glucan) is a class of polysaccharides built from D-glucose monomers linked through β-glycosidic bonds that routes them either into the colon as fermentable fiber (cereal form) or onto innate-immune cell surface receptors (yeast/mushroom form), with the structural difference between the two main types being the single most important fact because it determines mechanism, evidence base, dosage, regulatory pathway, and health-goal context.

Beta-Glucan (β-D-glucan · general CAS 9012-72-0 · individual source CAS values differ by extraction) is a class of polysaccharides built from D-glucose monomers linked through β-glycosidic bonds. The β-bond geometry — distinct from the α-bonds in starch and glycogen — makes β-glucans resistant to human digestive enzymes and routes them either into the colon as fermentable fiber (cereal form) or onto innate-immune cell surface receptors (yeast / mushroom form). The structural difference between the two main types is the single most important fact on this page, because it determines mechanism, evidence base, dosage, regulatory pathway, and which health-goal context the ingredient belongs in.

2.1 Two Main Structural Types · Side-by-Side

The single most important visual on this page. The entire downstream evidence and dosing structure depends on this distinction. A cholesterol-lowering claim made for a yeast β-glucan product, or an immune-support claim made for an oat β-glucan product, has no evidence base.

Dimension Cereal β-1,3/1,4-glucan Yeast / Mushroom β-1,3/1,6-glucan
Chemical structure Linear mixed-linkage β-1,3/1,4 backbone β-1,3 backbone with β-1,6 branches
Primary sources Oats (Avena sativa) · barley (Hordeum vulgare) Baker's / brewer's yeast (Saccharomyces cerevisiae) · shiitake · reishi · maitake · turkey tail · oyster mushroom
Physical form Water-soluble · forms high-viscosity gel in the small intestine Particulate / colloidal (partly insoluble) · does not form a viscous gel
Primary mechanism Viscous gel + bile-acid binding + delayed gastric emptying Dectin-1 + CR3 innate-immune receptor activation
Primary evidence direction LDL cholesterol lowering · post-meal blood glucose reduction · prebiotic / SCFA production Innate-immune support · respiratory immune resilience research · cancer-adjuvant research
FDA / EFSA / ANVISA authorized claims Three jurisdictions authorize cholesterol / heart-disease-risk-reduction claims at ≥3 g/day No EU EFSA authorization for yeast / mushroom immune claims (sold as supplements without claim in EU)

Why the two types must never be conflated. Cereal β-glucan's cholesterol- and glucose-modulating effects depend on the physical viscosity it creates in the small intestine — a mechanism that yeast and mushroom β-glucans cannot replicate because they do not form a viscous gel. Conversely, yeast and mushroom β-glucans engage immune receptors that cereal β-glucan does not bind in the same way. Throughout this fact sheet, every claim is labeled with its source qualifier.

2.2 Forms and Common Extracts

  • Whole-food cereal sources — oat bran · rolled oats · whole oat groats · whole / pearled barley · barley bran.
  • Cereal β-glucan concentrates / isolates — extracted oat or barley β-glucan used as food ingredients or fiber supplements. Processing that reduces molecular weight can reduce viscosity and therefore reduce efficacy (see §4 Ibrügger 2013 caveat).
  • Yeast-derived β-1,3/1,6-glucan — standardized particulate extracts from Saccharomyces cerevisiae cell walls, typically ≥75 % β-1,3/1,6 purity, supplied as 250–900 mg/day capsules.
  • Mushroom β-glucan extracts — shiitake · maitake · reishi · turkey tail β-glucan-rich extracts, with variable extraction methods and β-glucan content.
  • AHCC (Active Hexose Correlated Compound) — a low-molecular-weight (~5 kDa) mixed α-glucan / β-glucan polysaccharide preparation derived from shiitake (Lentinula edodes) mycelium fermentation. Mechanistically distinct from typical yeast β-glucan and used in emerging immune research contexts.

This page is part of ASXAN's evidence-first educational hub and does not constitute a purchase recommendation.

Mechanism of Action

Cereal and yeast/mushroom β-glucans act through entirely different biological pathways: cereal forms create a viscous gel for bile-acid binding and cholesterol-lowering, while yeast and mushroom forms engage innate-immune receptors (Dectin-1 and CR3) for immune activation, with conflating the two being the most common factual error in consumer communications.

Because cereal and yeast / mushroom β-glucans act through entirely different biological pathways, their mechanisms are described separately. Conflating them — or transferring a mechanism described for one type onto a product made from the other — is the most common factual error in consumer β-glucan communications.

3.1 Cereal β-1,3/1,4-Glucan · Viscous Gel and Bile-Acid Binding

Viscous gel formation and bile-acid binding (the cholesterol-lowering pathway). Oat and barley β-glucan enter the small intestine and absorb water to form a high-viscosity gel matrix that physically adsorbs bile acids. This interrupts the enterohepatic recirculation of bile acids — fecal bile-acid excretion rises, and the liver compensates by drawing cholesterol from circulating LDL-C to synthesize new bile acids. Serum LDL-C falls. The Wang 2017 RCT (PMID 29115200) demonstrated this directly by measuring fecal bile-acid output in barley β-glucan-supplemented adults.

Delayed gastric emptying and reduced post-meal blood glucose. The same viscous gel slows gastric emptying and reduces the rate at which glucose diffuses from the small-intestinal lumen across the absorption epithelium. Post-meal blood-glucose area-under-the-curve falls; the insulin secretion required to clear a given meal falls accordingly. The Tosh 2013 review of 34 trials quantified an average reduction of 48 ± 33 mmol·min/L in post-meal blood-glucose response across oat and barley β-glucan interventions.

Colonic fermentation and short-chain fatty acid production (prebiotic effect). Undigested β-glucan reaches the colon, where bifidobacteria, bacteroides, and other commensals ferment it to acetate, propionate, and butyrate. These short-chain fatty acids influence hepatic lipid metabolism, intestinal barrier integrity, and low-grade systemic inflammation. This is a secondary mechanism, modest in effect size relative to the primary viscous-gel pathway.

Key caveat — viscosity is the active principle. Processing or extraction steps that reduce β-glucan molecular weight reduce viscosity, and reduced viscosity reduces efficacy. The Ibrügger 2013 RCT (PMID 23946347) tested an extracted oat β-glucan preparation in young, healthy adults and found no significant effect on cholesterol — interpretable as a combination of molecular-weight loss during processing and a healthy baseline without a measurable cholesterol-lowering window. Product form and high molecular-weight preservation are decisive variables in clinical efficacy.

3.2 Yeast and Mushroom β-1,3/1,6-Glucan · Dectin-1 Receptor Activation

Dectin-1 + Complement Receptor 3 (CR3) innate-immune signaling. Particulate yeast and mushroom β-1,3/1,6-glucan reach the gut-associated lymphoid tissue via M-cell sampling in Peyer's patches, are processed and distributed systemically, and bind two principal innate-immune receptors on macrophages, neutrophils, and dendritic cells: Dectin-1 (CLEC7A) and CR3 (Mac-1 / CD11b/CD18). Receptor engagement activates the Syk-CARD9 signaling axis and downstream NF-κB transcription, upregulating cytokine production (TNF-α · IL-6 · IL-12) and antimicrobial peptide synthesis, and increasing macrophage phagocytic capacity, NK-cell cytotoxicity, and neutrophil oxidative-burst readiness.

Trained immunity (epigenetic reprogramming of innate cells). β-glucan is one of the most extensively characterized inducers of trained immunity — long-lasting epigenetic changes (H3K4me3 and H3K27ac histone modifications at innate-immune gene promoters) that prime myeloid cells to respond more vigorously to subsequent infectious stimuli, even after the original β-glucan signal has been cleared. This mechanism underpins the directionality of the respiratory immune research described in §4.

Complement activation and bridging to adaptive immunity. β-1,3/1,6-glucan activates the alternative complement pathway, generating C3b opsonins that bind tumor-cell or pathogen surfaces and enable CR3-mediated cytotoxicity. This is the mechanistic basis for mushroom β-glucan's use in adjuvant cancer research described in §4 — strictly as adjunct to standard chemotherapy or radiotherapy, never as a standalone intervention.

AHCC mechanistic note. AHCC is a mixed-polysaccharide preparation from shiitake mycelium and is not equivalent to purified yeast β-glucan. Its lower molecular weight and α/β mixed composition appear to drive NK-cell and dendritic-cell activation through partly distinct pathways. Mechanistic detail remains under active study; pilot clinical findings in immune-research contexts are reported in §4 with explicit emerging-evidence caveats.

Mechanism-vs-clinical-translation note. Cereal β-glucan's mechanism evidence in humans is unusually direct (Wang 2017 measured fecal bile acids · Tosh 2013 measured post-meal glucose AUC). Yeast and mushroom β-glucan mechanisms are well characterized at the receptor level, but the clinical translation in randomized human trials is more modest in effect size and more heterogeneous between studies — a pattern reflected in the evidence tiers in §4.

References: PMID 25411276 · PMID 27724985 · PMID 23946347 · PMID 23340963 · PMID 33900466.

Evidence-Based Benefits

Evidence is segmented by structural source. Every claim below carries a source qualifier ("Oat / barley β-glucan…" or "Yeast β-1,3/1,6-glucan…" or "Mushroom β-glucan / AHCC…") because the two main types are not interchangeable. Evidence tier labels follow NIH-ODS conventions: meta-analysis-supported > rct-supported > emerging > preclinical-major. Effect sizes are reported as published.

4.1 Cereal β-Glucan · Cardiovascular and Cholesterol Support

Meta-analysis supported

Oat and barley β-glucan at ≥3 g/day reduces LDL cholesterol across multiple meta-analyses with consistent dose-response relationships, supporting cholesterol maintenance as part of a heart-healthy diet.

  • 3 MAMeta-analyses
  • 0.25 mmol/LLDL-C reduction
  • 21 CFR 101.81 + Reg 432/2012 + Reg 1228/2014Authorized health claims

Evidence Tier: meta-analysis-supported (oat / barley β-glucan only — does not apply to yeast or mushroom forms)

Educational notice: Hypercholesterolemia (ICD-10 E78) and coronary heart disease (ICD-10 I20–I25) are clinical diagnoses requiring medical evaluation. The data below describe oat and barley β-glucan's effects on LDL cholesterol and related cardiovascular risk markers; they do not establish β-glucan as a treatment or cure for any heart or lipid disorder. Individuals on statin or other lipid-modifying therapy should not modify their treatment regimen without consulting their cardiologist or primary care provider.

A 2014 systematic review and meta-analysis of 28 RCTs (Whitehead et al., American Journal of Clinical Nutrition) reported that oat β-glucan at ≥3 g/day reduced LDL-C by 0.25 mmol/L (95 % CI −0.30 to −0.20) and total cholesterol by 0.30 mmol/L versus control, with a positive dose–response relationship across the studied range.

A 2016 systematic review and meta-analysis of 58 trials in 3,974 participants (Ho et al., British Journal of Nutrition) — using a median dose of 3.5 g oat β-glucan per day — reported reductions of 0.19 mmol/L in LDL-C, 0.20 mmol/L in non-HDL-C, and 0.03 g/L in apolipoprotein B versus control. The simultaneous reduction across three correlated cardiovascular risk markers strengthens the inference of a coherent biological effect on atherogenic lipoprotein particles.

A 2022 systematic review and meta-analysis of 13 RCTs in 927 hypercholesterolemic adults (Yu et al., Nutrients) further confirmed significant reductions in total cholesterol and LDL-C, with no significant effect on triglycerides or HDL-C, and reported that the magnitude of effect depended on baseline cholesterol level, intervention duration, β-glucan source, and dose.

Authorized health claim references. The US FDA has authorized, under 21 CFR 101.81 (1997 final rule with subsequent amendments incorporating oatrim in 2002, whole-grain barley in 2005, and barley betafiber in 2008), the claim that "Soluble fiber from foods such as [name of food source], as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease" — with claim conditions requiring ≥0.75 g β-glucan soluble fiber per labeled serving and a total daily intake of ≥3 g (four servings per day). The European Food Safety Authority has authorized, under Regulation (EU) No 432/2012 Article 13(1), the claim that "Beta-glucans contribute to the maintenance of normal blood cholesterol levels" (condition: ≥1 g β-glucan from oats, oat bran, barley, barley bran, or mixtures per labeled serving · consumers informed that ≥3 g/day is required for the effect), and under Commission Regulation (EU) No 1228/2014 Article 14 the disease risk reduction claim that "Oat beta-glucan has been shown to lower / reduce blood cholesterol. Blood cholesterol lowering may reduce the risk of (coronary) heart disease" — one of a small number of formally authorized "may reduce the risk of disease" claims in the supplement domain. The Brazilian ANVISA does not authorize a specific Anexo V alegação funcional for β-glucan under IN 28/2018. β-glucan from oat bran and from yeast (Saccharomyces cerevisiae) are listed in Anexo I as authorized supplement constituents under RDC 243/2018 dietary supplement framework, but Anexo V fiber claims are limited to psyllium (≥ 7 g/day) and chitosan (≥ 3 g/day). Brazilian product labeling cannot use a verbatim ANVISA-authorized functional claim for β-glucan cholesterol reduction equivalent to FDA / EFSA wording — and cross-border product compliance requires market-specific claim wording.

These data support oat and barley β-glucan at ≥3 g/day as a dietary approach to maintaining healthy blood cholesterol and — in jurisdictions that recognize the FDA and EFSA wording — as potentially contributing to reduced coronary-heart-disease risk as part of a heart-healthy diet. They do not support claims that β-glucan "treats high cholesterol," "cures heart disease," or substitutes for statin or other prescribed lipid therapy.

References: PMID 25411276 · PMID 27724985 · PMID 35631184.

4.2 Cereal β-Glucan · Post-Meal Blood Glucose Response

Meta-analysis supported

Oat and barley β-glucan at ≥4 g per 30 g of available carbohydrates per meal significantly reduces post-meal blood-glucose rise with dose- and molecular-weight-dependent effects.

  • 35 RCTs (103 comparisons)Acute post-meal glucose studies
  • 48 ± 33 mmol·min/LAverage post-meal glucose reduction
  • EFSA Reg 432/2012 Art.13(1)Authorized claim condition

Evidence Tier: meta-analysis-supported (oat / barley β-glucan only)

Educational notice: Type 2 diabetes mellitus (ICD-10 E11) is a clinical diagnosis that requires medical management. The data below evaluate cereal β-glucan's effect on the post-meal blood-glucose rise in research populations; they do not establish β-glucan as a treatment for diabetes or as a substitute for prescribed glucose-lowering medication. Individuals taking insulin, sulfonylureas, or other glucose-lowering drugs should consult their healthcare provider before adding cereal β-glucan to a meal pattern, because added blood-glucose lowering could increase hypoglycemia risk.

A 2021 systematic review and meta-analysis of 35 acute cross-over RCTs comprising 103 individual comparisons in 538 participants (Zurbau et al., European Journal of Clinical Nutrition) reported that consumption of oat β-glucan as part of a meal significantly reduced the post-meal blood-glucose and insulin area-under-the-curve, with both dose-dependent and molecular-weight-dependent effects: higher β-glucan dose and higher molecular weight produced larger reductions in glycemic response.

A 2013 narrative review of 76 human studies, with 34 trials meeting inclusion criteria for quantitative regression (Tosh, European Journal of Clinical Nutrition), reported that oat and barley β-glucan reduced post-meal blood-glucose response by an average of 48 ± 33 mmol·min/L across interventions, with intact whole-grain forms producing larger effects than processed foods — again pointing to molecular weight and food matrix as critical variables.

Authorized health claim reference. EFSA has authorized, under Regulation (EU) No 432/2012 Article 13(1), the claim that "Consumption of beta-glucans from oats or barley as part of a meal contributes to the reduction of the blood glucose rise after that meal" — with the condition that the food contains ≥4 g β-glucan from oats or barley for each 30 g of available carbohydrates per serving, consumed as part of the meal. The US FDA has not issued a separate post-meal-glycemia health claim for β-glucan; in US labeling, post-meal glycemic effects can be discussed under structure / function claim conventions. Brazilian ANVISA has not issued an Anexo V alegação funcional for β-glucan glycemic response under IN 28/2018.

These data support cereal β-glucan, at ≥4 g per 30 g of available carbohydrates per meal, as a dietary approach to reducing the post-meal blood-glucose rise. They do not support claims that β-glucan "treats diabetes," "lowers blood sugar in diabetics," or substitutes for prescribed glucose-lowering therapy. Cereal β-glucan also fits naturally alongside other meal-pattern interventions for individuals managing GLP-1 therapy or general weight-management contexts (see /goals/glp-1-companion/ and /goals/weight-management/).

References: PMID 33608654 · Tosh 2013 (Eur J Clin Nutr 67:310–317 · DOI 10.1038/ejcn.2013.25).

4.3 Yeast β-1,3/1,6-Glucan · Immune System Function Research

RCT supported

Yeast β-1,3/1,6-glucan (250–900 mg/day) supports immune system function in research populations with effect sizes modest and comparable to daily vitamin D in respiratory-immune research.

  • 2 RCTs + 1 MAYeast immune evidence base
  • Modest reduction with heterogeneityEffect on infection frequency
  • 250-900 mg/day standardized extractResearch-aligned dosing

Evidence Tier: rct-supported (yeast β-1,3/1,6-glucan only — does not apply to cereal forms)

Educational notice: Acute upper-respiratory-tract infections — including the common cold, influenza, COVID-19, and other viral or bacterial respiratory illnesses — are medical conditions. Yeast β-glucan is not authorized as a treatment, cure, or specific preventive therapy for any named respiratory illness. The data below describe research findings on yeast β-glucan supplementation and immune-system-function endpoints, including respiratory-symptom outcomes measured in research populations.

A 2013 double-blind, placebo-controlled RCT of 162 healthy adults with self-reported recurring infections (Auinger et al., European Journal of Nutrition) administered yeast-derived β-1,3/1,6-glucan 900 mg/day for 16 weeks. The β-glucan group reported a significant reduction in the frequency of symptomatic infections, a lower mean symptom score, and improvements in sleep-difficulty self-reports versus placebo.

A 2017 double-blind, placebo-controlled RCT of 98 community-dwelling adults aged 50–70 years (Fuller et al., Nutrition) administered yeast β-1,3/1,6-glucan 250 mg/day for 90 days through the winter season. The β-glucan group experienced a lower burden of respiratory-tract symptoms and a shorter duration of symptoms when they did occur. Supplementation was well tolerated.

A 2021 systematic review and meta-analysis of multiple RCTs (Zhong et al., European Journal of Nutrition) on yeast β-glucan for respiratory-tract infection prevention and treatment reported a modest but directionally consistent reduction in infection frequency and symptom duration, with substantial heterogeneity across studies in dose, duration, and population. The authors noted that standardization of dose and source would strengthen future evidence synthesis.

The effect sizes reported across this evidence base are modest — comparable in magnitude to those reported for daily vitamin D in respiratory-immune research (see /ingredients/vitamin-d3/). These data support yeast β-1,3/1,6-glucan as a research-supported nutritional approach to supporting immune system function during seasonal periods of higher respiratory immune challenge. They do not support claims that yeast β-glucan "prevents colds," "treats flu," or "stops COVID infection."

EU regulatory note. Yeast and mushroom β-glucan products do not currently hold an EFSA-authorized health claim in the European Union. In the EU, yeast and mushroom β-glucan products are sold as dietary supplements without immune-related claims on labeling or advertising. Cross-border e-commerce intended for the EU market must strip immune-related claim language to comply.

References: PMID 23340963 · PMID 28606567 · PMID 33900466.

Dosage

β-glucan dosing depends entirely on which structural type and health-goal context is being addressed, with the most important rule that doses validated for one form are not transferable to the other, and whole-food sources being preferable for cereal β-glucan while standardized extracts are typically required for yeast/mushroom immune research doses.

β-glucan dosing depends entirely on which structural type and which health-goal context is being addressed. The most important rule is that doses validated for one form are not transferable to the other. Whole-food sources are preferable for cereal β-glucan; standardized extracts are typically required to reach the doses used in yeast / mushroom immune research.

Source + Direction Validated dose Typical onset Source
Oat / barley β-glucan · cholesterol support ≥3 g/day (FDA + EFSA authorized claim threshold) · e.g., 0.75 g per serving × 4 servings/day 4–8 weeks onset · 8–12+ weeks for full effect Whitehead 2014 · Ho 2016 · Yu 2022
Oat / barley β-glucan · post-meal glucose ≥4 g per 30 g of available carbohydrates per meal (EFSA Reg 432/2012 condition) Acute (per-meal effect) Zurbau 2021 · Tosh 2013
Yeast β-1,3/1,6-glucan · immune system function research 250–900 mg/day of ≥75 % purity standardized extract 8–16+ weeks continuous; seasonal start ≥4 weeks before window of interest Fuller 2017 (250 mg/day × 90 d) · Auinger 2013 (900 mg/day × 16 wk)
Mushroom β-glucan · immune support (variable by extract) 100–500 mg/day (variability across species and extraction methods is high) Continuous supplementation General body of immune-research literature
AHCC · emerging immune research 1–3 g/day (within Smith 2019 pilot range) 5 weeks – 6 months (pilot data only) Smith 2019 pilot series

Key dosing principles.

  • Form and molecular weight matter for cereal β-glucan. The Ibrügger 2013 negative finding (§4.5) is the most concrete reminder that extracted, low-molecular-weight β-glucan preparations may not deliver the cholesterol effect that intact, high-viscosity oat or barley sources deliver. Where the goal is cholesterol or post-meal-glucose effects, whole-grain food sources are the most reliable form.
  • Yeast / mushroom β-1,3/1,6-glucan purity is the quality threshold. Standardized extracts at ≥75 % β-1,3/1,6 purity are the basis of the published immune-research dosing.
  • Cross-border ceiling — China yeast β-glucan. China's NMPA recognizes yeast β-glucan as a New Food Ingredient with a published upper intake of 250 mg/day for adults (2010 New Food Ingredient notice). Cross-market products targeting the Chinese consumer must respect this ceiling.

Regulatory framework — four jurisdictions, segmented by source.

Market Cereal source Yeast / mushroom source Key authorized claim wording
US FDA Recognized as soluble dietary fiber · ≥3 g/day claim qualifying GRAS · structure / function claim conventions for immune support 21 CFR 101.81 authorized health claim: "Soluble fiber from foods such as [oat / barley source], as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease" (≥0.75 g per serving · ≥3 g/day total)
EU EFSA Multiple authorized claims for cereal sources No EFSA-authorized health claim for yeast or mushroom β-glucan immune effects — sold without immune claim in EU Reg 432/2012 Art.13(1) "Beta-glucans contribute to the maintenance of normal blood cholesterol levels" (≥1 g/serving · ≥3 g/day) · Reg 432/2012 Art.13(1) "Consumption of beta-glucans from oats or barley as part of a meal contributes to the reduction of the blood glucose rise after that meal" (≥4 g per 30 g available carbohydrates) · Reg 1228/2014 Art.14 "Oat beta-glucan has been shown to lower / reduce blood cholesterol. Blood cholesterol lowering may reduce the risk of (coronary) heart disease"
BR ANVISA Anexo I authorized supplement constituent only — NO Anexo V functional claim for β-glucan (Anexo V fiber claims limited to psyllium ≥7 g/d and chitosan ≥3 g/d) Case-by-case regulatory pathway for yeast extracts; no functional claim equivalent to cereal cholesterol No ANVISA-authorized functional claim for β-glucan — Anexo I constituent status only; BR labeling cannot use FDA/EFSA cholesterol wording
CN NMPA Oat β-glucan recognized as New Food Ingredient · general food use permitted Yeast β-glucan New Food Ingredient (2010 notice) UL ≤250 mg/day · mushroom polysaccharides have registered Health Food precedents Registered Health Food function categories (e.g., "enhances immune function") require product-level NMPA approval

Individual response varies. Consult a healthcare provider for personalized dosage assessment, particularly if you are taking glucose-lowering or lipid-modifying medication, are pregnant or lactating, have autoimmune disease, are post-organ-transplant or on immunosuppressive therapy, or have any chronic condition.

Safety and Drug Interactions

Cereal β-glucan has an excellent safety profile rooted in millennia of dietary use of oats and barley as staple grains. Yeast and mushroom β-glucans also have long histories of dietary exposure (yeast in fermented foods, mushrooms in traditional food and medicinal use), though concentrated extracts at supplemental doses are more recent and carry specific cautions tied to their immune-activating mechanism.

6.1 Cereal β-Glucan Safety

  • No formal upper intake limit; FDA GRAS as a dietary fiber.
  • Common, mild gastrointestinal effects. Higher initial intakes can cause bloating or flatulence during the first 4–8 weeks of supplementation, reflecting normal colonic fermentation; these typically subside as the gut microbiota adapts. Gradual dose escalation reduces this transient effect.
  • Cautions.
    • Celiac disease and non-celiac gluten sensitivity — oats are botanically gluten-free, but conventional oat processing facilities often share equipment with wheat, barley, and rye. Individuals with celiac disease should choose certified gluten-free oat sources.
    • Severe intestinal obstruction or short-bowel syndrome — high-fiber supplementation is generally cautioned and should be discussed with a gastroenterologist.

6.2 Yeast / Mushroom β-Glucan Safety

  • China NMPA upper intake — yeast β-glucan ≤250 mg/day (per 2010 New Food Ingredient notice). Other jurisdictions do not set a formal UL but published clinical doses cluster at 250–900 mg/day.
  • Adverse events are uncommon with high-purity (≥75 %) β-1,3/1,6 yeast extracts, which have largely removed residual yeast protein associated with allergenicity.
  • Important cautions tied to immune-activating mechanism.
    • Autoimmune disease — use with caution and medical supervision. Yeast and mushroom β-glucans are innate-immune receptor ligands and could, in principle, amplify already-heightened immune responses. This is especially relevant in systemic lupus erythematosus (SLE) · rheumatoid arthritis (RA) · multiple sclerosis (MS) · inflammatory bowel disease (IBD) · Crohn's disease · psoriasis · and autoimmune thyroid disease. Individuals with diagnosed autoimmune disease should not start yeast or mushroom β-glucan supplementation without explicit consultation with their rheumatologist or treating specialist.
    • Post-organ-transplant or active immunosuppressive therapy — generally contraindicated. β-glucan's immune-activating mechanism is directionally opposite to the therapeutic intent of immunosuppressive regimens used after solid-organ transplant or for some autoimmune conditions; concurrent use should be avoided.
    • Yeast allergy — verify residual yeast-protein content and allergen labeling.

6.3 Drug Interactions

  • Glucose-lowering medication (insulin · sulfonylureas · GLP-1 receptor agonists) + cereal β-glucan ≥4 g per meal → additive lowering of post-meal blood glucose. Individuals on glucose-lowering therapy should monitor blood glucose closely when adding cereal β-glucan and discuss potential dose adjustments with their healthcare provider to avoid hypoglycemia.
  • Statin or other lipid-modifying therapy + cereal β-glucan ≥3 g/day → additive cholesterol-lowering effect; any change to prescribed lipid therapy must be made by the prescribing clinician, not on the basis of cereal β-glucan addition alone.
  • Immunosuppressive therapy + yeast / mushroom β-glucan → mechanistically antagonistic; avoid concurrent use during organ-transplant maintenance and during active immunosuppressive treatment for autoimmune disease.
  • High-dose cereal β-glucan + warfarin or other anticoagulants → theoretical effect on absorption of fat-soluble vitamins (including vitamin K) at very high fiber intakes; clinical significance is not established, but INR monitoring is prudent if high-fiber intake changes substantially.

6.4 Special Populations

  • Glycogen storage disease. Certain glycogen storage disease subtypes involve carbohydrate-metabolism abnormalities for which high β-glucan intake should be evaluated by the treating metabolic-disease specialist.
  • Pregnancy and lactation. Cereal β-glucan as part of dietary oats and barley is consistent with standard prenatal nutrition guidance. Concentrated yeast or mushroom β-glucan extract supplementation in pregnancy and lactation has limited data and should be discussed with an obstetric provider before use.

References: PMID 23340963 · PMID 28606567 · PMID 33309412.

Food Sources versus Supplements

Where the health goal is cholesterol or post-meal blood-glucose support, whole-food cereal sources are the first and most reliable choice. Where the goal is yeast / mushroom immune-research dosing, standardized supplemental extracts are typically required because food-form mushroom and yeast intakes do not deliver enough β-glucan to match the doses used in published research.

7.1 Cereal β-Glucan · Whole-Food First

Food β-glucan content (g per 100 g dry) Practical serving Path to ≥3 g/day
Oat bran (raw) ~5.5–7.0 g 40 g (3–4 heaped tablespoons) ~1.5 servings/day (e.g., two bowls of oat-bran porridge)
Rolled oats (old-fashioned) ~3.5–4.5 g 40 g (~1 cup dry) ~2 servings/day (e.g., breakfast bowl + savory oat bowl)
Whole oat groats ~5.0 g 40 g ~1.5 servings/day
Whole / pearled barley ~3.0–5.0 g 50 g ~2 servings/day (e.g., barley instead of rice at one meal)

Practical pattern. A daily 1-cup serving of rolled oats plus one meal substituting barley for rice approximates the ≥3 g/day FDA / EFSA cholesterol threshold. Whole-food forms preserve the high molecular weight and viscous-gel-forming capacity on which the cholesterol and glucose mechanisms depend, and the Ibrügger 2013 negative finding (§4.5) is the cautionary counterexample for extracted, low-molecular-weight preparations.

7.2 Yeast / Mushroom β-Glucan · Supplements Often Required to Reach Research Doses

  • Edible mushrooms (shiitake · reishi · maitake · turkey tail · oyster) contain β-glucan, but cooking losses and variability between species mean that ordinary culinary servings rarely reach the supplemental dose ranges used in the immune-research literature.
  • Brewer's / nutritional yeast contains β-glucan but at a relatively low purity within a complex matrix.
  • For the doses used in yeast or mushroom β-glucan immune research, standardized supplemental extracts (≥75 % β-1,3/1,6 purity for yeast; defined β-glucan content for mushroom extracts) are typically required. Consumers selecting supplements should verify (a) the source organism, (b) the β-glucan content and purity, (c) the molecular-weight specification or extraction method where relevant, and (d) third-party identity and contaminant testing.

7.3 General Guidance

  • Prioritize whole-food oats and barley to reach the ≥3 g/day cereal β-glucan threshold for cholesterol and the per-meal threshold for post-meal glucose support.
  • If adding yeast or mushroom β-glucan for immune-research-aligned support, select a standardized extract appropriate to the published research dose range, and review the safety cautions in §6 (autoimmune disease · post-transplant · immunosuppressive therapy · pregnancy).

Regulatory Status · Three-Tier Distinction Preserved

β-glucan is one of the few supplement-domain ingredients to hold three distinct regulatory authorizations across major jurisdictions — and the type of authorization differs by jurisdiction, which matters for product labeling, advertising, and cross-border trade.

8.1 US FDA · 21 CFR 101.81 Disease Risk Reduction Claim (Cereal Only)

Legal basis. 21 CFR 101.81 — "Health claims: Soluble fiber from certain foods and risk of coronary heart disease (CHD)."

Timeline. 1997 January final rule (whole oats · rolled oats · oat bran · whole oat flour · oatrim); 2002 oatrim amendment; 2005 December extension to whole-grain barley and dry-milled barley; 2008 February amendment incorporating barley betafiber.

Authorized claim wording (exact). "Soluble fiber from foods such as [name of food source], as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease. A serving of [name of food] supplies [__] grams of the [necessary daily dietary intake for the benefit] soluble fiber from [name of food source] necessary per day to have this effect."

Conditions. ≥0.75 g β-glucan soluble fiber per labeled serving; four servings/day reaching the ≥3 g/day threshold. Limited to whole oats / rolled oats / oat bran / whole oat flour / oatrim / whole-grain barley / dry-milled barley / barley betafiber sources.

8.2 EU EFSA · Regulation 432/2012 Article 13(1) and 1228/2014 Article 14 (Cereal Only)

Article 13(1) cholesterol-maintenance claim. "Beta-glucans contribute to the maintenance of normal blood cholesterol levels." Condition: ≥1 g β-glucan from oats / oat bran / barley / barley bran (or mixtures) per labeled serving; consumers informed that the beneficial effect is obtained with daily intake of ≥3 g of β-glucans from oats / oat bran / barley / barley bran or mixtures of these β-glucans.

Article 13(1) post-meal glycemia claim. "Consumption of beta-glucans from oats or barley as part of a meal contributes to the reduction of the blood glucose rise after that meal." Condition: the food contains ≥4 g β-glucan from oats or barley for each 30 g of available carbohydrates in a quantified portion as part of the meal.

Article 14 disease risk reduction claim (Reg 1228/2014). "Oat beta-glucan has been shown to lower / reduce blood cholesterol. Blood cholesterol lowering may reduce the risk of (coronary) heart disease." This is one of a small number of "may reduce the risk of disease" claims in the EU supplement framework.

Recent activity. EFSA reassessments in 2025 (EFSA Journal 9630, Article 13(1) postprandial glycemia) and 2026 (EFSA Journal 9942, Article 13(5) postprandial glucose peak) have maintained or refined existing positive opinions, reflecting an ongoing and supportive EFSA position on cereal β-glucan.

EU position on yeast / mushroom β-glucan. EFSA has not authorized a health claim for yeast or mushroom β-glucan immune effects. Products marketed in the EU may be sold as dietary supplements but must not carry immune-related claims on labels or in advertising.

8.3 BR ANVISA · Authorized Constituent without Specific Anexo V Functional Claim

Under IN 28/2018 Anexo I, ANVISA recognizes Beta-glucana de farelo de aveia and Beta-glucana de levedura (Saccharomyces cerevisiae) as authorized supplement constituents within the RDC 243/2018 dietary supplement framework. However, IN 28/2018 Anexo V does not list a specific alegação funcional for β-glucan — the only Anexo V fiber-related cholesterol claims are for psyllium (≥ 7 g/day) and chitosan (≥ 3 g/day). Consequently, Brazilian product labeling and advertising cannot use a verbatim ANVISA-authorized functional claim equivalent to the FDA 21 CFR 101.81 or EFSA Reg 432/2012 wording for β-glucan. Cross-border products targeting the Brazilian market must rely on the Anexo I authorized constituent status and avoid functional claim language for β-glucan in the local market.

8.4 CN NMPA · New Food Ingredient and Health Food Pathways

  • Oat β-glucan — recognized as a New Food Ingredient; general food use is permitted.
  • Yeast β-glucan — recognized as a New Food Ingredient under the 2010 NMPA notice, with a published upper intake of 250 mg/day for adults. Cross-market products targeting Chinese consumers must respect this ceiling.
  • Mushroom polysaccharides — have registered Health Food precedents; product-level NMPA registration is required for specific function claims (for example, "enhances immune function").

8.5 Educational Hub Direct-Quotation Position

This page is part of ASXAN's evidence-first educational hub and may directly quote the FDA, EFSA, and ANVISA authorized wording above with its associated conditions. The same wording is not used to imply that cereal β-glucan treats or cures cholesterol or cardiovascular disease, that yeast or mushroom β-glucan prevents respiratory illness, or that mushroom β-glucan or AHCC treats cancer or HPV infection. The boundary between "authorized risk-reduction or functional language" and "treatment / cure claim" is preserved throughout.

How to Choose a Quality β-Glucan Product

Because the two structural types are used for different goals and have different quality dimensions, selection criteria differ by form.

For cereal β-glucan (cholesterol or post-meal glucose support):

  • Prefer whole-food sources — rolled oats, oat bran, whole oat groats, whole or pearled barley — to preserve the high molecular weight and viscous-gel-forming capacity that drive efficacy.
  • If a fiber-supplement product is preferred, look for clear declaration of β-glucan content per serving (target ≥0.75 g per serving · ≥3 g/day total) and avoid low-molecular-weight extracts where viscosity has been engineered out (the Ibrügger 2013 negative finding in §4.5 is the cautionary case).
  • For celiac disease or non-celiac gluten sensitivity, use certified gluten-free oat sources.

For yeast β-1,3/1,6-glucan (immune-research-aligned support):

  • Standardized extract at ≥75 % β-1,3/1,6 purity is the consensus quality threshold reflected in the published clinical research.
  • Look for clear declaration of source organism (Saccharomyces cerevisiae), dose per serving aligned with the 250–900 mg/day published range, and third-party identity and contaminant testing.
  • Review the safety cautions in §6 (autoimmune disease · post-transplant · immunosuppressive therapy · pregnancy) before initiating.

For mushroom β-glucan and AHCC:

  • Verify the source species (shiitake · reishi · maitake · turkey tail · oyster), the extraction method, and the β-glucan content of the finished extract.
  • AHCC is a specific shiitake-mycelium-derived preparation and is not interchangeable with general mushroom β-glucan extracts.
  • The clinical research is emerging rather than meta-analytic; product choices here should be made with this evidence stage in mind and, in clinical contexts (active cancer treatment, persistent HPV), only with treating-specialist guidance.

This page does not endorse specific brands; consumers selecting any supplemental form are encouraged to consult third-party testing certifications, allergen labeling, and their healthcare provider.

β-glucan does not sit within a single hub topic cluster but bridges several. Related fact sheets on this hub include:

  • /ingredients/vitamin-d3/ — daily-dose immune research; the modest effect-size frame for yeast β-glucan respiratory-immune research is best read alongside the modest effect-size frame for vitamin D respiratory-immune research.
  • /ingredients/omega-3/ — cardiovascular evidence base; cereal β-glucan's authorized cholesterol claim sits alongside omega-3's distinct mechanism of action on triglycerides and cardiovascular risk markers.
  • /ingredients/astaxanthin/ — antioxidant evidence base; positioned within a broader cellular-protection context rather than the lipid- or immune-receptor pathways described on this page.
  • /goals/glp-1-companion/ and /goals/weight-management/ — cereal β-glucan's per-meal glycemic-response claim is a natural complement to broader meal-pattern interventions for individuals managing GLP-1 therapy or weight goals.

References

All PMIDs verified against PubMed (2026-05-24). Effect sizes are reported as published.

Cereal β-Glucan · Cholesterol (§4.1)

  1. PMID 25411276 · Whitehead A et al. (2014) · American Journal of Clinical Nutrition 100(6):1413-21 · Meta-analysis of 28 RCTs · oat β-glucan ≥3 g/day · LDL-C ↓ 0.25 mmol/L · TC ↓ 0.30 mmol/L
  2. PMID 27724985 · Ho HV et al. (2016) · British Journal of Nutrition · SR + MA of 58 trials n=3,974 · median 3.5 g/day · LDL-C ↓ 0.19 mmol/L · non-HDL-C ↓ 0.20 mmol/L · apoB ↓ 0.03 g/L
  3. PMID 35631184 · Yu J et al. (2022) · Nutrients · SR + MA of 13 RCTs n=927 hypercholesterolemic adults · TC and LDL-C significantly reduced · TG and HDL-C non-significant

Cereal β-Glucan · Post-Meal Glucose (§4.2)

  1. PMID 33608654 · Zurbau A et al. (2021) · European Journal of Clinical Nutrition 75(11):1540-1554 · SR + MA of 35 acute cross-over RCTs · 103 comparisons n=538 · post-meal glucose and insulin AUC ↓ · dose- and molecular-weight-dependent
  2. Tosh S (2013) · European Journal of Clinical Nutrition 67:310-317 · DOI 10.1038/ejcn.2013.25 · Review of 76 human studies · 34 included for regression · average post-meal glucose response ↓ 48 ± 33 mmol·min/L

Cereal β-Glucan · Negative / Mixed (§4.5)

  1. PMID 23946347 · Ibrügger S et al. (2013) · Journal of Nutrition 143(10):1579-85 · DB RCT in young, healthy adults · extracted oat β-glucan no significant cholesterol reduction — form and molecular-weight cautionary case

Yeast β-Glucan · Immune Research (§4.3)

  1. PMID 23340963 · Auinger A et al. (2013) · European Journal of Nutrition · DB-PC RCT n=162 healthy adults with recurring infections · yeast β-1,3/1,6-glucan 900 mg/day × 16 weeks · symptomatic infection frequency ↓ · mean symptom score ↓ · sleep difficulties improved
  2. PMID 28606567 · Fuller R et al. (2017) · Nutrition (Burbank) · DB-PC RCT n=98 community-dwelling adults 50-70 y · yeast β-1,3/1,6-glucan 250 mg/day × 90 days winter season · symptom burden and duration ↓ · well tolerated
  3. PMID 33900466 · Zhong K et al. (2021) · European Journal of Nutrition 60(8):4175-4187 · SR + MA · yeast β-glucan for respiratory-tract infection prevention and treatment · modest reduction with substantial between-study heterogeneity

Mushroom β-Glucan and AHCC · Emerging Research (§4.4)

  1. PMID 33309412 · Steimbach L et al. (2021) · Clinical Nutrition 40(5):3104-3113 · SR of 16 cancer clinical trials n=1,650 across 9 cancer types · 1992-2018 · fungal β-glucan as adjunct to chemotherapy / radiotherapy only — reduced treatment-induced immune suppression · accelerated WBC recovery · improved QoL
  2. Smith JA et al. (2019) · Frontiers in Oncology · Two pilot studies n=10 per arm · women with confirmed persistent high-risk HPV >2 y · AHCC 1-3 g/day for 5 weeks to 6 months · pilot signal of clearance in a subset — emerging evidence only · no preventive or treatment claim supported

Regulatory References (Not Counted in PMID Total)

  • US FDA 21 CFR 101.81 (1997 final rule with subsequent amendments — 2002 oatrim · 2005 whole-grain barley · 2008 barley betafiber) — Soluble fiber from oats / barley and risk of coronary heart disease authorized health claim
  • EU EFSA Regulation (EU) No 432/2012 Article 13(1) — Cereal β-glucan cholesterol-maintenance and post-meal glycemia function claims
  • EU EFSA Commission Regulation (EU) No 1228/2014 Article 14 — Oat β-glucan disease risk reduction claim (cholesterol → coronary heart disease risk)
  • EU EFSA Journal 9630 (2025) and EFSA Journal 9942 (2026) — EFSA reassessments maintaining the cereal β-glucan postprandial glycemia evidence base
  • BR ANVISA IN 28/2018 Anexo I — β-glucan (oat bran and yeast Saccharomyces cerevisiae) as authorized supplement constituent under RDC 243/2018 framework; no specific Anexo V alegação funcional for β-glucan
  • CN NMPA New Food Ingredient notices — Oat β-glucan (general food use); yeast β-glucan (2010 notice · adult UL 250 mg/day); mushroom polysaccharides registered Health Food precedents

FAQ · Common Confusions

1. What is the difference between oat / barley β-glucan and yeast or mushroom β-glucan — are they interchangeable?

No. They are structurally different molecules (β-1,3/1,4 linear in cereal vs β-1,3/1,6 branched in yeast / mushroom) with different mechanisms (viscous gel + bile-acid binding for cereal vs Dectin-1 receptor activation for yeast / mushroom), different evidence directions (cholesterol and glucose for cereal vs immune function for yeast / mushroom), and different regulatory authorizations. Doses and claims established for one form do not apply to the other. See §1 and §2 above.

2. How much oat β-glucan do I need per day for the cholesterol effect?

The FDA 21 CFR 101.81 and EFSA Article 14 authorized claims are conditioned on a daily intake of ≥3 g of oat or barley β-glucan, taken as part of a diet low in saturated fat and cholesterol. About 1 cup of rolled oats plus one barley-for-rice substitution reaches this threshold. Effects typically appear over 4–12 weeks of consistent intake.

3. I have type 2 diabetes — can I take oat β-glucan?

Cereal β-glucan can reduce the post-meal blood-glucose rise (EFSA Article 13(1) authorized for ≥4 g per 30 g of available carbohydrates per meal). However, type 2 diabetes is a clinical diagnosis and people on insulin, sulfonylureas, or other glucose-lowering medication should consult their healthcare provider before adding cereal β-glucan, because additive lowering of blood glucose could increase the risk of hypoglycemia. Do not stop or change prescribed therapy on the basis of dietary β-glucan intake.

4. I have heart disease or high cholesterol — can β-glucan replace my statin?

No. The FDA and EFSA wording is "may reduce the risk of heart disease" as part of a heart-healthy diet — not a treatment for diagnosed cardiovascular disease and not a substitute for prescribed lipid therapy. Decisions about prescription medication must be made with the prescribing clinician. Cereal β-glucan may be one component of a broader diet pattern within that medical plan.

5. Will β-glucan prevent COVID-19, flu, or the common cold?

No. Yeast β-1,3/1,6-glucan has randomized evidence supporting immune system function in research populations, with effect sizes comparable to daily vitamin D in respiratory-immune research. The evidence does not support claims that β-glucan prevents, treats, or cures COVID-19, influenza, the common cold, or any other named respiratory illness. Vaccination and other evidence-based preventive measures should be discussed with your healthcare provider.

6. Does AHCC clear HPV or treat cervical disease?

No. The current AHCC HPV evidence base consists of two small pilot studies (Smith 2019) with 10 participants per arm and Phase II trials in progress. The data are reported in §4.4 for educational transparency. AHCC is not characterized on this page as a treatment, cure, or preventive therapy for HPV infection, cervical disease, or any other named condition. Persistent HPV infection requires medical evaluation and management.

7. Can β-glucan be used to prevent or treat cancer?

No. The Steimbach 2021 systematic review summarized 16 trials of fungal β-glucan used as an adjunct to standard chemotherapy or radiotherapy under medical supervision and reported reductions in treatment-induced immune suppression. It does not support cancer prevention or standalone cancer treatment claims. Cancer prevention and treatment decisions must be made with an oncologist.

8. I have an autoimmune disease (lupus, RA, MS, IBD, psoriasis, autoimmune thyroid disease) — can I take yeast or mushroom β-glucan?

Use with caution and medical supervision. Yeast and mushroom β-glucans are innate-immune receptor ligands and could in principle amplify already-heightened immune responses. Do not start yeast or mushroom β-glucan supplementation without explicit consultation with your rheumatologist or treating specialist. Cereal (oat / barley) β-glucan, used as dietary fiber for cholesterol or glucose support, operates through a different mechanism and is not typically subject to the same caution — but any supplement decision in the context of autoimmune disease should be discussed with the treating clinician.

9. Why does the EU allow oat β-glucan cholesterol claims but not yeast β-glucan immune claims?

The EFSA evaluation framework requires authorized health claims to meet defined evidence thresholds. Cereal β-glucan and cholesterol / post-meal glucose claims have cleared this threshold (Regulations 432/2012 and 1228/2014). Yeast and mushroom β-glucan immune claims have not received EFSA authorization to date, so they may not appear on labels or in advertising in the EU. Cross-border e-commerce intended for the EU must strip immune-related claim language from yeast / mushroom β-glucan product communications.

10. Are there drug interactions or safety cautions I should be aware of?

Yes — see §6 above. The most important points are: glucose-lowering medication plus cereal β-glucan can additively lower blood glucose (monitor for hypoglycemia); statins and cereal β-glucan additively lower cholesterol (do not modify prescribed therapy without your clinician); immunosuppressive therapy and yeast / mushroom β-glucan are mechanistically antagonistic (generally avoid); and individuals with autoimmune disease, recent transplant, glycogen storage disease, celiac disease (use certified gluten-free oats), or pregnancy / lactation should consult a healthcare provider before initiating supplemental β-glucan.

← Evidence library

Ask Agent Axor